Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. (TMO) Market Cap

Thermo Fisher Scientific Inc. has a market capitalization of $195.62B.

Financials based on reported quarter end 2025-12-31

Price: $526.60

β–² 10.60 (2.05%)

Market Cap: 195.62B

NYSE Β· time unavailable

CEO: Marc N. Casper

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1980-03-17

Website: https://www.thermofisher.com

Thermo Fisher Scientific Inc. (TMO) - Company Information

Market Cap: 195.62B Β· Sector: Healthcare

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Analyst Sentiment

83%
Strong Buy

Based on 28 ratings

Analyst 1Y Forecast: $623.71

Average target (based on 6 sources)

Consensus Price Target

Low

$580

Median

$653

High

$750

Average

$657

Potential Upside: 24.8%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ Thermo Fisher Scientific Inc. (TMO) β€” Investment Overview

🧩 Business Model Overview

Thermo Fisher Scientific operates as a diversified leader in the life sciences and laboratory supply industry, delivering a broad suite of products, instruments, software, and services to the global scientific community. Its offerings span laboratory equipment, analytical instruments, reagents and chemicals, specialty diagnostics, and cutting-edge research tools. Thermo Fisher serves a wide-ranging customer base including pharmaceutical and biotech companies, academic and government research institutions, clinical laboratories, and industrial clients. The company’s footprint extends across multiple end-markets, such as healthcare, diagnostics, research and development, environmental monitoring, and applied sciences, positioning it at the nexus of innovation in scientific advancements and healthcare delivery.

πŸ’° Revenue Model & Ecosystem

Thermo Fisher generates revenue through a multi-faceted approach encompassing equipment sales, reagents and consumables, proprietary software platforms, and specialized services. Significant portions of its sales are based on recurring purchases, notably reagents, consumables, and service contracts, which complement the company’s installed base of laboratory instruments. Subscriptions for software and informatics solutions further enhance customer engagement and data-driven workflows. The company also provides comprehensive support, consulting, and project services, thereby embedding itself more deeply in its clients’ value chains. Its ecosystem is built to facilitate long-term relationships, supplying both enterprise and institutional customers with end-to-end solutions for their evolving scientific needs.

🧠 Competitive Advantages

  • Brand strength: Thermo Fisher is widely recognized as a trusted partner in scientific innovation and laboratory solutions, with a longstanding reputation for quality and reliability.
  • Switching costs: The interconnected nature of its instruments, software, and consumables creates high switching costs for institutions reliant on integrated workflows and data compatibility.
  • Ecosystem stickiness: Through bundled offerings, broad product lines, and seamless workflow integration, the company embeds itself within critical research and operational functions of its customers.
  • Scale + supply chain leverage: As one of the industry’s largest players, Thermo Fisher leverages significant purchasing power, extensive global distribution, and manufacturing efficiencies, supporting resilient operations and competitive pricing.

πŸš€ Growth Drivers Ahead

Thermo Fisher is positioned for sustained growth through multiple long-term catalysts. Rising investments in biopharmaceutical R&D and personalized medicine continue to drive demand for advanced analytical and diagnostic solutions. The accelerating adoption of genomics, proteomics, and cell therapy technologies opens up new markets for high-value instruments and consumables. The company’s strategic focus on expanding into emerging markets and broadening its digital and informatics capabilities offers incremental growth opportunities. In addition, its track record of targeted acquisitions and partnerships facilitates entry into adjacent verticals and enhances overall value for customers. Ongoing public and private sector initiatives aimed at advancing healthcare quality and safety further reinforce the essential nature of Thermo Fisher's solutions.

⚠ Risk Factors to Monitor

Several risk factors warrant close consideration. The highly competitive nature of the life sciences industry places continual pressure on innovation, pricing, and market share. Rapid technological change and emerging disruptive solutions could potentially erode the company’s leading positions. Regulatory complexities in global healthcare and diagnostics markets require vigilance and adaptability, with evolving standards or compliance costs impacting operations. Additionally, margin pressures from shifts in funding sources, customer consolidation, or supply chain disruptions present potential challenges to profitability. Execution risks tied to integration of acquisitions and international expansion also remain key watchpoints.

πŸ“Š Valuation Perspective

Thermo Fisher has historically commanded a premium valuation relative to many of its sector peers, reflecting both its scale and perceived resilience of its diverse business model. The market views its comprehensive product ecosystem, recurring revenue streams, and consistent execution as merits supporting higher investor confidence. Investors often consider the company’s balanced exposure to both growth-oriented and stable end-markets as contributing factors to its valuation positioning.

πŸ” Investment Takeaway

Thermo Fisher Scientific stands out for its robust business model, deep customer integration, and leadership across core scientific domains. The bull case centers on long-term secular growth in life sciences, expanding applications for laboratory solutions, and ongoing strategic execution driving diversification and resilience. The bear case reflects risks from intensifying competition, regulatory and macroeconomic uncertainties, and the potential for disruptive innovation to alter current industry dynamics. Overall, Thermo Fisher offers a compelling blend of growth potential and defensive attributes, making it a prominent player for consideration within the healthcare and life sciences investment universe.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Thermo Fisher Scientific Inc. reported Q4 2025 revenue of $12.21 billion and net income of $1.98 billion, translating to an EPS of $5.22. The company registered a net margin of 16.2%. Cash flow from operations reached $3.46 billion, with free cash flow at $2.99 billion. Year-over-year growth shows stable revenue expansion and solid profitability. The firm has effectively managed its debt, with net debt standing at $29.53 billion against total equity of $53.54 billion, indicating financial solidity. Despite substantial stock repurchases of $3 billion in the quarter, Thermo Fisher continues to reward shareholders with quarterly dividends, maintaining a consistent $0.43 per share payout. Analyst sentiment remains cautiously optimistic, with a consensus price target of $643.69. The company shows resilience in maintaining operational efficiency, continual investment in capital expenditures, and robust returns to shareholders. However, careful attention is required regarding its leverage and the pace of its substantial share repurchase program."

Revenue Growth

Good

Revenue growth is stable with $12.21 billion in the latest quarter, driven by strong operations and consistent demand.

Profitability

Good

Healthy net margin of 16.2% and EPS of $5.22 reflect strong cost management and profitability.

Cash Flow Quality

Good

Free cash flow is strong at $2.99 billion, supporting a robust share repurchase program and consistent dividends.

Leverage & Balance Sheet

Positive

Net debt is manageable at $29.53 billion but requires monitoring relative to equity and cash reserves.

Shareholder Returns

Good

Strong shareholder returns through dividends and significant stock repurchases, showcasing commitment to return capital.

Analyst Sentiment & Valuation

Positive

Valuation is supported by a consensus target of $643.69; however, high leverage may weigh on market sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Thermo Fisher delivered a strong Q4 and solid full-year 2025 with outperformance vs guidance, led by strength in bioproduction, Specialty Diagnostics, electron microscopy, and improving clinical research. The company advanced its strategy through high-impact innovation, AI initiatives, and active capital deployment including acquisitions to bolster bioproduction, clinical research, and digital endpoints. Despite tariffs and FX headwinds and weakness in academic/government and China, management guided to 4–6% reported revenue growth and 6–8% EPS growth in 2026, signaling confidence and continued share gains.

Growth

  • Q4 reported revenue +7% to $12.21B; organic +3%, acquisitions +2%, FX +2%
  • FY25 reported revenue +4% to $44.56B; organic +2%, acquisitions +1%, FX +1%
  • Pharma & biotech: high-single-digit growth in Q4; mid-single-digit for FY25, led by bioproduction and Research & Safety Market Channel
  • Diagnostics & healthcare: low-single-digit growth in Q4; flat for FY25 (strength in transplant diagnostics and immunodiagnostics)
  • Industrial & applied: low-single-digit decline in Q4; low-single-digit growth for FY25 (electron microscopy strength)
  • Academic & government: low-single-digit declines in Q4 and FY25
  • Geography Q4: North America low-single-digit growth; Europe mid-single-digit; APAC low-single-digit with China low-single-digit decline; FY25 China mid-single-digit decline

Business Development

  • Launched Orbitrap Astro Zoom mass spectrometer with higher sensitivity and speed
  • Expanded single-use bioproduction with Thermo Scientific 5L DynaDrive bioreactor
  • Introduced new cryo-TEM for structural biology; launched Helios MX-one plasma FIB-SEM for semiconductor analysis
  • Ion Torrent OncoMindDx received additional FDA approval as a companion diagnostic (Bayer therapy for certain NSCLC patients)
  • Exens system received US 510(k) clearance for earlier multiple myeloma diagnosis
  • Formed technology alliance with Chan Zuckerberg for advanced biological imaging
  • Announced strategic collaboration with OpenAI to embed AI in operations and products
  • Expanded bioprocess design centers in Asia with a new site in India

Financials

  • Q4 adjusted operating income $2.88B (+6%); adjusted operating margin 23.6% (-30 bps YoY)
  • Q4 adjusted EPS $6.57 (+8%); GAAP EPS $5.21
  • FY25 adjusted operating income $10.11B (+4%); adjusted operating margin 22.7% (+10 bps YoY)
  • FY25 adjusted EPS $22.87 (+5%); GAAP EPS $17.74
  • Q4 results exceeded prior guidance: revenue ~$250M ahead; adjusted EPS $0.14 ahead (+$0.25 operations, -$0.11 FX)

Capital & Funding

  • Deployed ~$16.5B in 2025: ~$13B committed to M&A; returned $3.6B via buybacks and dividends
  • Acquired filtration and separation business from Solventa to extend bioproduction capabilities
  • Acquired Sanofi’s sterile fill-finish site in New Jersey to expand US drug product manufacturing
  • Announced definitive agreement to acquire Claria (digital endpoint data solutions; ~$1.5B 2025 revenue); expected accretive to organic growth, adjusted margin, and +$0.45 adjusted EPS in first 12 months; targeted close by 2026

Operations & Strategy

  • PPI business system drove cost management, operational excellence, and agility amid tariffs/FX headwinds
  • Embedding AI into PPI to streamline processes and enhance customer service
  • Trusted partner strategy and commercial engine underpin share gains
  • Accelerator (integrated CDMO/CRO) solution secured meaningful wins, reducing development timelines and improving R&D ROI

Market & Outlook

  • Initiated 2026 revenue guidance: $46.3–$47.2B (+4–6% reported; assumes +3–4% organic growth)
  • Initiated 2026 adjusted EPS: $24.22–$24.80 (+6–8%)
  • Expect continued share gains and strong operational performance in 2026
  • Navigating tariffs and US policy dynamics; customers supported through changing environment

Risks Or Headwinds

  • Tariffs and related FX created >100 bps headwind to margins in Q4 and FY25
  • FX volatility due to trade tensions; incremental ~65 bps margin headwind vs prior guidance in Q4
  • Macro softness in US and China pressured academic/government end markets
  • China declined mid-single digits for FY25

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the TMO Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (TMO)

Β© 2026 Stock Market Info β€” Thermo Fisher Scientific Inc. (TMO) Financial Profile